Dr. Richard H. Tullis, Ph.D. serves as a Consultant at Aethlon Medical, Inc. Dr. Tullis served as Chief Scientific Officer of Aethlon Medical Inc. (formerly Bishop Equities Inc) from June 1, 2001 to January 10, 2017 and served as its Senior Vice President until January 10, 2017. He served as Vice President at Aethlon Medical, Inc. Dr. Tullis has extensive biotechnology management and research experience and is the Founder of Syngen Research Inc., a wholly-owned subsidiary of Aethlon Medical Inc. He co-founded Molecular Biosystems Inc., a former NYSE company. He served as Vice President of Business Development at Aethlon Medical Inc. At Molecular Biosystems, he served as a Director of Research and Development, Director of Oligonucleotide Hybridization, Senior Research Scientist and Member of the Board of Directors. In research, Dr. Tullis developed and patented the first application of oligonucleotides to antisense antibiotics and developed new methods for the chemical synthesis of DNA via methoxy-phosphorochloridites. He also Co-developed the first applications of covalently coupled DNA-enzyme conjugates using synthetic oligonucleotides during his tenure at Molecular Biosystems. In 1985, Dr. Tullis founded and served as President and Chief Executive Officer of Synthetic Genetics Inc., a pioneer in custom DNA synthesis, which was sold to Molecular Biology Resources in 1991. He served as Interim-Chief Executive Officer of Genetic Vectors Inc., which completed its IPO under his management and was co-founder of DNA Sciences Inc., a company that was eventually acquired by Genetic Vectors. He served as Director of Aethlon Medical Inc. from January 2000 to June 5, 2015 and served as Member of Scientific Advisory Board. Dr. Tullis received his Ph.D. in Biochemistry and Cell Biology from the University of California at San Diego and has done extensive post-doctoral work at UCSD, USC, the University of Hawaii and The Scripps Research Institute.